In vitro activity of Tityus metuendus and Brotheas amazonicus scorpion venoms against Plasmodium falciparum FRC3

---

Original Article

Author Details : Daiane Barão Pereira, Jonas Gama Martins, Yohonatan Alain Duque Aurazo, Rudi Emerson de Lima Procópio*

Volume : 10, Issue : 1, Year : 2024

Article Page : 24-28

https://doi.org/10.18231/j.ijmmtd.2024.005

Suggest article by email

Get Permission

---

Abstract

Introduction: Scorpion venoms contain different classes of molecules with possible pharmacological activities, making them sources of bioactive molecules for the development of new drugs against infections caused by pathogens, such as malaria, a disease caused by protozoa of the genus Plasmodium. Malaria faces challenges in its control due to pathogen resistance to available antimalarials.
Materials and Methods: In this study, we evaluated the venom activity of the Amazonian scorpions Tityus metuendus and Brotheas amazonicus against Plasmodium falciparum FRC3, the analysis was performed by flow cytometry.
Results: At the analyzed concentrations, we found that the crude venom of B. amazonicus had an average inhibition of 87% at the concentration of 100 g/mL, above that obtained with the drug (quinine), which had mean inhibition of 84% against P. falciparum FCR3. Regarding the venom of T. metuendus, lower activity was observed in comparison with the inhibition potential of the B. amazonicus venom and the standard drug, B. amazonicus venom showed low toxicity against the human fibroblast MRC5.
Conclusion: Because peptides and toxins from scorpion venom are related to biological functions, they can be used in the design of new therapeutic agents, with B. amazonicus venom being a possible source of molecules for the development of antimalarial drugs.

Keywords : Scorpion, Venoms Antimalarial, Antiplasmodial, Plasmodium falciparum

How to cite : Pereira D B, Martins J G, Aurazo Y A D, Procópio R E D L, In vitro activity of Tityus metuendus and Brotheas amazonicus scorpion venoms against Plasmodium falciparum FRC3. IP Int J Med Microbiol Trop Dis 2024;10(1):24-28

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.